



Date: 14/11/2024

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14th November, 2024

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. 14th November, 2024, has considered and approved the following:

1. Quarterly Standalone Financial Results of the Company for the quarter ended on 30th September, 2024 along with the Limited Review Report thereon; (enclosed)

We wish to inform you that the Board Meeting commenced today at 03.30 p.m. and concluded at 8.55 p.m.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

**Apurva Bandivadekar
Company Secretary & Compliance Officer**

Encl: as above

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com
CIN No. L99999MH1993PLC072892

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Bajaj Healthcare Limited ('the Company') for the quarter ended 30 September 2024 and the year to date results for the period 1 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Bajaj Healthcare Limited
Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

YASHWANT
MANGILAL JAIN

Digitally signed by
YASHWANT MANGILAL
JAIN
Date: 2024.11.14 21:09:04
+05'30'

Yashwant M. Jain

Partner

Membership No. 118782

UDIN: 24118782BKHJOS6500

Place: Mumbai

Date: 14 November 2024

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
FINANCIAL RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER, 2024

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Period Ended		Year Ended
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A. Continuing Operations						
I. Revenue from operations	13,308.92	13,224.67	10,120.96	26,533.59	23,094.64	47,341.79
II. Other Income	260.67	85.41	121.71	346.08	143.52	868.63
III. Total Income (I+II)	13,569.59	13,310.08	10,242.67	26,879.67	23,238.16	48,210.42
IV. Expenses						
(a) Cost of materials consumed	5,503.25	7,891.29	5,102.32	13,394.54	12,714.90	26,442.76
(b) Changes in Inventories of Finished Good	1,094.67	(1,333.00)	(617.01)	(238.33)	(736.62)	(965.52)
(c) Employee benefits expense	1,399.35	1,270.59	1,111.52	2,669.94	2,157.98	4,384.54
(d) Finance Costs	787.60	844.41	826.38	1,632.01	1,701.46	2,967.98
(e) Depreciation and amortisation expense	680.64	672.99	666.01	1,353.63	1,296.74	2,761.95
(f) Other expenses	2,859.23	2,945.39	2,629.09	5,804.62	4,888.87	9,853.45
Total Expenses	12,324.74	12,291.67	9,718.31	24,616.41	22,023.33	45,445.16
V. Profit before Exceptional Items and Tax Expense	1,244.85	1,018.41	524.36	2,263.26	1,214.83	2,765.26
VI. Exceptional items (Refer Note g)	-	-	-	-	-	4,432.81
VII. Profit/(Loss) Before Tax	1,244.85	1,018.41	524.36	2,263.26	1,214.83	(1,667.55)
VIII. Tax Expense						
(a) Current tax	-	-	-	-	-	-
(b) Current tax-Earlier Years	-	-	-	-	-	135.64
(c) Deferred Tax Charge/ (Credit)	410.48	215.78	12.04	626.26	(0.14)	(370.53)
Total Tax Expenses	410.48	215.78	12.04	626.26	(0.14)	(234.89)
IX. Profit/ (Loss) after Tax from Continuing Operations	834.37	802.63	512.32	1,637.00	1,214.97	(1,432.66)
B. Discontinued Operations						
X. Loss before Tax from Discontinued Operations	(83.38)	(111.97)	(970.40)	(195.35)	(6,656.87)	(8,718.96)
XI. Tax Expense / (Credit) of Discontinued Operations	(195.44)	(22.53)	(111.99)	(217.97)	(274.65)	(1,772.31)
XII. Profit/(Loss) after Tax from Discontinued Operations	112.06	(89.44)	(858.41)	22.62	(6,382.22)	(6,946.65)
XIII. Profit/ (Loss) for the period / year (IX +XII)	946.43	713.19	(346.09)	1,659.62	(5,167.25)	(8,379.31)
XIV. Other comprehensive Income						
Continuing Operations						
(i) Items that will not be reclassified to profit or loss	(92.72)	(92.73)	17.07	(185.45)	17.07	(370.92)
(ii) Income tax relating to items that will not be reclassified to profit or loss	23.34	23.34	(4.30)	46.68	(4.30)	93.36
Total Other Comprehensive Income from Continuing Operations	(69.38)	(69.39)	12.77	(138.77)	12.77	(277.56)
Discontinued Operations						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income from Discontinued Operations	-	-	-	-	-	-
XV. Total Comprehensive Income for the Period / Year	877.05	643.80	(333.32)	1,520.85	(5,154.48)	(8,656.87)
XVI. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,579.16	1,379.92	1,379.92	1,579.16	1,379.92	1,379.92
XVII. Other Equity				43,003.67	-	26,456.17
XVIII. EPS (Not Annualised for the Quarter)						
Continuing Operations						
(a) Basic & Diluted (in Rs.)	2.96	2.91	1.86	5.87	4.40	(5.19)
Discontinued Operations						
(a) Basic & Diluted (in Rs.)	0.40	(0.32)	(3.11)	0.08	(23.13)	(25.17)
Total Operations						
(a) Basic & Diluted (in Rs.)	3.36	2.59	(1.25)	5.95	(18.73)	(30.36)



SIGNED FOR
IDENTIFICATION
PURPOSES ONLY



Note :

- a) The above financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 14 November 2024 and subjected to limited review carried out by Statutory Auditors who have expressed unmodified review conclusion.
- b) The above unaudited financial results for the quarter and six months period ended 30 September, 2024 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS) 34 on "Interim financial Reporting", as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015 as amended.
- c) The Company deals in pharmaceuticals products ("formulations and active pharmaceutical ingredients components") which are interlinked and interdependent. Therefore, the Company identified only one reportable segment i.e. Pharmaceuticals.
- d) The Board of Directors in their meeting held on 28 June 2023 approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no. E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. Approval of shareholders was obtained vide postal ballot. The management continues to classify the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal in accordance with Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Out of the above undertakings/units, one unit situated at plot no. N-92 was sold during the quarter ended 31 March, 2024.

Particulars	Quarter Ended			Period Ended		Year Ended
	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
Total Income (A)	24.34	6.13	629.90	30.48	1,320.11	1,784.51
Total Expenses (B)	107.72	118.10	1,600.30	225.83	7,976.98	10,503.47
Loss before Tax from Discontinued Operations (C = A - B)	(83.38)	(111.97)	(970.40)	(195.35)	(6,656.87)	(8,718.96)
Tax Expense / (Credit) from Discontinued Operations (D)	(195.44)	(22.53)	(111.99)	(217.97)	(274.65)	(1,772.31)
Loss after Tax from Discontinued Operations (E = C - D)	112.06	(89.44)	(858.41)	22.62	(6,382.22)	(6,946.65)

e) The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting ("EGM") held on Wednesday, 07 August, 2024 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") approved, the issue of 40,44,852/- Equity Shares at Rs 338/- share to Person(s) belonging to non promoter category on preferential basis and the issue of convertible equity warrants 20,79,409/- at Rs 338/- to Person(s) belonging to promoter category as well as non promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purpose. The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, Board of directors have approved allotment of 39,84,852 no. of equity shares and has also filed the relevant form with Registrar of Companies.

f) The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.

Particulars	Rs. (in Lakhs)
Repayment & prepayment of secured/unsecured loans from bank/NBFC	15,000.00
General corporate purpose	225.90
Total	15,225.90

g) During the previous year, the Company had written off inventories pertaining to certain covid portfolio products owing to continued lower demand, on a conservative basis.

h) Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, which are not material.



Date : 14 November 2024
Place: Thane

For and on Behalf of the Board
For Bajaj Healthcare Limited

ANIL
CHAMPALAL JAIN

Mr. Anil C Jain
D.No.: 00226137
Jt. Managing Director

Digitally signed by ANIL
CHAMPALAL JAIN
Date: 2024.11.14 20:56:06
+05'30'



SIGNED FOR
IDENTIFICATION
PURPOSES ONLY

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

BALANCE SHEET AS AT 30 SEPTEMBER 2024

(Rs in Lakhs)

Particulars	As at	As at
	30.09.2024	31.03.2024
	(Unaudited)	(Audited)
A ASSETS		
1 Non-current assets		
(a) Property Plant & Equipment	23,800.15	25,204.92
(b) Right to Use Assets	60.20	70.52
(c) Other Intangible Assets	176.08	
(d) Capital work-in-progress	968.97	480.38
(e) Intangible Assets Under Development	-	181.28
(f) Financial Assets		
(i) Long Term Investments	0.33	0.33
(ii) Other Financial assets	342.70	270.00
(g) Current tax Assets(Net)	115.39	114.39
(h) Deferred tax Assets [Net]	1,824.10	2,185.71
Total Non Current Assets	27,287.92	28,507.53
2 Current assets		
(a) Inventories	14,243.03	14,403.82
(b) Financial Assets		
(i) Trade receivables	21,685.60	18,024.00
(ii) Cash and cash equivalents	2,146.79	217.47
(iii)Bank Balance other than(ii) above	137.21	75.41
(iv) Other Financial assets	3,516.08	3,502.57
(c) Other Current Assets	3,827.13	4,230.99
Total Current assets	45,555.84	40,454.26
Non Current assets classified as Held for sale	7,550.98	7,550.98
TOTAL ASSETS	80,394.74	76,512.77
B EQUITY AND LIABILITIES		
1 Equity		
(a) Share Capital	1,579.16	1,379.92
(b) Other Equity	43,003.67	26,456.17
Total Equity	44,582.83	27,836.09
2 Non-Current Liabilities		
i) Financial Liabilities		
a) Borrowings	3,127.64	3,857.81
b) Lease Liabilities	47.02	57.03
ii) Provisions	612.21	613.92
Total Non-Current Liabilities	3,786.87	4,528.76
3 Current Liabilities		
a) Financial Liabilities		
i) Borrowings	17,379.71	29,349.12
ii) Lease Liabilities	19.87	18.47
iii) Trade Payables		
- Total outstanding dues of Small Enterprises and Micro enterprises	529.79	215.04
-Total outstanding dues of creditors other than small enterprises and micro enterprises	8,516.77	8,727.61
iv) Other Financial Liabilities	1,486.97	1,641.54
b) Other Current Liabilities	629.48	246.68
c) Provisions	233.51	12.35
Total Current Liabilities	28,796.10	40,210.81
Liabilities Associated with Assets held for sale	3,228.94	3,937.11
Total Equity and Liabilities	80,394.74	76,512.77



By Order of the Board
For Bajaj Healthcare Limited

**ANIL CHAMPALAL
JAIN**

Digitally signed by ANIL
CHAMPALAL JAIN
Date: 2024.11.14 20:57:01
+05'30'

Mr. Anil C Jain
D.No.: 00226137
Jt. Managing Director

Date : 14 November 2024
Place: Thane

SIGNED FOR
IDENTIFICATION
PURPOSES ONLY

Bajaj Healthcare Limited
STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 30 SEPTEMBER, 2024
CIN: L99999MH1993PLC072892

(Rs. In Lakhs)

Sr No	Particulars	For the Period Ended 30 September 2024 (Unaudited)		For the Period Ended 30 September, 2023 (Unaudited)	
A	CASH FLOW FROM OPERATING ACTIVITIES				
	(Loss)/Profit before tax		2,067.91		(5,442.04)
	Continuing operations	2,263.26		1,214.83	
	Discontinuing operations	(195.35)		(6,656.87)	
	Adjustments for:				
	Depreciation	1,353.63		1,679.51	
	Loss on sale of Property Plant & Equipment	33.49		(2.62)	
	Finance Cost	1,769.87		2,127.01	
	Interest on Fixed deposits	(11.25)		(10.04)	
	Provision for Employee Benefits & Leave Enchashment	36.34		43.75	
	Interest Income on Security Deposit	(0.40)		(0.25)	
	Unrealised Foreign Exchange Gain	(269.46)		-	
	Loss on fair value of Non current assets classified as held for sale	-		4,358.91	
	Allowance for expected credit loss	375.00		56.14	
			3,287.22		8,252.41
Operating Profit before Working Capital Changes		5,355.13		2,810.37	
Adjustments for:					
Decrease in non current and current Assets	390.34		599.67		
(Increase)/Decrease In Trade receivable	(3,940.76)		693.23		
Decrease In Inventories	160.79		205.31		
Increase/(Decrease) in non current and current liabilities	606.67		(81.58)		
		(2,782.96)		1,416.63	
Cash generated from operations		2,572.17		4,227.00	
Income Tax Paid		(1.00)	(70.14)	(70.14)	
Net Cash flow generated from Operating activities		2,571.17		4,156.86	
B	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Property Plant & Equipment (including assets under development)	(574.25)		(2,248.94)	
	Proceeds from sale of Property Plant & Equipment	118.80		2.07	
	Interest on deposits	11.64		10.04	
	Increase in Bank balances not considered as cash and cash equivalent	(61.80)		-	
	Investment in fixed deposits	(72.70)		-	
	Net Cash used in Investing activities		(578.31)		(2,236.83)
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Proceeds from long term borrowing (Net)	(1,924.96)		(32.99)	
	Repayment of from short term borrowing (Net)	(10,999.85)		(968.02)	
	Repayment of borrowing from Director & Inter corpoates (Net)	(582.93)		(1.30)	
	Payment of lease liabilities	(11.83)		(11.29)	
	Interest paid	(1,769.87)		(2,127.01)	
	Proceeds from issue of equity shares and share warrants including securities premium	15,225.90		-	
Net Cash used in from financing activities		(63.54)		(3,140.61)	
Net increase in Cash & Cash Equivalents (A+B+C)			1,929.32		(1,220.58)
Opening balance of Cash and Cash equivalents at on Beginning of the period			217.47		1,772.04
Closing balance of Cash and Cash equivalents at End of the period			2,146.79		551.46



SIGNED FOR
IDENTIFICATION
PURPOSES ONLY



For and on behalf of the Board
of Bajaj Healthcare Ltd

ANIL
CHAMPALAL JAIN
Digitally signed by ANIL
CHAMPALAL JAIN
Date: 2024.11.14
20:54:39 +05'30'

Mr. Anil C Jain
Jt. Managing Director

D.No.: 00226137

Date : 14 November 2024
Place: Thane